Recent market research reveals that glucagon-like peptide-1 (GLP-1) injections are set to dominate the obesity treatment ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Putting tariffs on Denmark unless it cedes the island of Greenland could hurt access to a few key products, including popular ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 484.89% and ...

Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...

"The Republican Party will not cut benefits," Republican House Speaker Mike Johnson said. Also in the news: Medicare drug price negotiations, the House transgender bathroom ban, and more.

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Minutes from the meeting will be published at 2 p.m. Eastern on Wednesday. The Federal Open Market Committee-the Fed's policymaking committee-last month voted to lower the federal-funds rate target ...